Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocept Inc (NQ: BIOC )

0.3400 -0.0125 (-3.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biocept Inc

< Previous 1 2 Next >
Enrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal Metastases
From Biocept, Inc.
Via Business Wire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Biocept, Inc.
Via Business Wire
Biocept to Explore Strategic Alternatives and Implement Restructuring Plan
From Biocept, Inc.
Via Business Wire
Biocept Reports Third Quarter 2022 Financial Results
From Biocept, Inc.
Via Business Wire
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
From Biocept, Inc.
Via Business Wire
Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Biocept Reports Second Quarter 2022 Financial Results
From Biocept, Inc.
Via Business Wire
Biocept to Present at the LD Micro Main Event XV
From Biocept, Inc.
Via Business Wire
Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Biocept, Inc.
Via Business Wire
Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q
From Biocept, Inc.
Via Business Wire
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
From Biocept, Inc.
Via Business Wire
Biocept Appoints RSM as Independent Auditor
From Biocept, Inc.
Via Business Wire
Biocept to Hold Business Strategy Conference Call Today
From Biocept, Inc.
Via Business Wire
Biocept Reports First Quarter 2022 Financial Results
From Biocept, Inc.
Via Business Wire
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
From Biocept, Inc.
Via Business Wire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Biocept, Inc.
Via Business Wire
Biocept Reports 2021 Fourth Quarter and Full Year Financial Results
From Biocept, Inc.
Via Business Wire
Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance
From Biocept, Inc.
Via Business Wire
Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022
From Biocept, Inc.
Via Business Wire
Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer
From Biocept, Inc.
Via Business Wire
Introduction of Innovative PCR-Based Detection Methods Surges Fueled by Pandemic and Other Diseases
Palm Beach, FL – February 18, 2022 – FinancialNewsMedia.com News Commentary – PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few... 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer
From Biocept, Inc.
Via Business Wire
Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer
From Biocept, Inc.
Via Business Wire
Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
From Biocept, Inc.
Via Business Wire
Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10
From Biocept, Inc.
Via Business Wire
Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain
From Biocept, Inc.
Via Business Wire
Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
From Biocept, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.